-
PolarityTE Stock Drops On FDA Clinical Hold On SkinTE Trial Application
Tuesday, August 24, 2021 - 1:17pm | 275Read More...The FDA has issued a clinical hold on PolarityTE Inc's (NASDAQ: PTE) SkinTE Investigational New Drug Application (IND) for chronic cutaneous ulcers. The FDA provided feedback on certain Chemistry, Manufacturing, and Control (CMC) items that need to be addressed before...
-
InflaRx's Vilobelimab Shows Encouraging Signs Of Drug Activity In Mid-Stage Study With Dermatological Ulcer Patients
Tuesday, August 10, 2021 - 9:17am | 279Read More...InflaRx N.V. (NASDAQ: IFRX) has announced data from the first 10 evaluable patients in the ongoing Phase 2a open-label study with vilobelimab in Pyoderma Gangraenosum (PG). PG is a rare condition that causes large, painful sores (ulcers) to develop on the skin, most often on the...
-
PolarityTE Stock Jumps As SkinTE Aces Diabetic Foot Ulcer Trial
Monday, May 10, 2021 - 9:06am | 347Read More...PolarityTE Inc (NASDAQ: PTE) has announced preliminary topline data from a multi-center randomized controlled trial evaluating SkinTE for the treatment of Diabetic Foot Ulcers. The 100-subject trial, which assessed SkinTE plus standard of care (SOC) vs. SOC alone, met...
-
Aralez Pharmaceuticals Volatile Following FDA Approval Of Yosprala
Monday, March 28, 2016 - 1:29pm | 172Read More...Shares of Aralez Pharmaceuticals Inc (NASDAQ: ARLZ) were volatile on Monday after the company announced the U.S. Food and Drug Administration accepted the company's New Drug Application for its investigational candidate, YOSPRALA. Shares of Aralez opened for trading at $3.73 and spiked to...
